KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for Vir Biotechnology (VIR) over the last 8 years, with Q2 2025 value amounting to $10.1 million.

  • Vir Biotechnology's Current Deferred Revenue fell 3947.43% to $10.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.1 million, marking a year-over-year decrease of 3947.43%. This contributed to the annual value of $12.6 million for FY2024, which is 8049.74% down from last year.
  • As of Q2 2025, Vir Biotechnology's Current Deferred Revenue stood at $10.1 million, which was down 3947.43% from $11.9 million recorded in Q1 2025.
  • Over the past 5 years, Vir Biotechnology's Current Deferred Revenue peaked at $262.9 million during Q1 2021, and registered a low of $10.1 million during Q2 2025.
  • For the 5-year period, Vir Biotechnology's Current Deferred Revenue averaged around $48.0 million, with its median value being $16.2 million (2023).
  • In the last 5 years, Vir Biotechnology's Current Deferred Revenue soared by 514808.38% in 2021 and then crashed by 9410.49% in 2022.
  • Quarter analysis of 5 years shows Vir Biotechnology's Current Deferred Revenue stood at $98.2 million in 2021, then plummeted by 84.2% to $15.5 million in 2022, then surged by 317.95% to $64.9 million in 2023, then crashed by 80.5% to $12.6 million in 2024, then fell by 20.07% to $10.1 million in 2025.
  • Its Current Deferred Revenue stands at $10.1 million for Q2 2025, versus $11.9 million for Q1 2025 and $12.6 million for Q4 2024.